TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06491485
Drug: Group M (lidocaine with Magnesium sulfate)
Normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a total volume 200 ml normal saline 0.9% at a temperature of 37°c including 3mg/kg of 1% lidocaine with magnesium sulfate 50 mg/kg (maximum 2g) will be sprayed by the surgeon through the laparoscopic port to wash the incisions and anastomosis.
Study: NCT06491485
Drug: Group B (lidocaine with Sodium bicarbonate)
Normalized name: meningococcal group B vaccine
DrugBank: Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen (DB10284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a total volume 200 ml normal saline 0.9% at a temperature of 37°c including 3mg/kg of 1% lidocaine with 50 ml 4.2% sodium bicarbonate will be sprayed by the surgeon through the laparoscopic port to wash the incisions and anastomosis.
Study: NCT06491485
Drug: Group C (lidocaine with saline)
Normalized name: meningococcal group C polysaccharide
DrugBank: Neisseria meningitidis group c capsular polysaccharide diphtheria toxoid conjugate antigen (DB10799)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a total volume 200 ml normal saline 0.9% at a temperature of 37°c including 3mg/kg of 1% lidocaine will be sprayed by the surgeon through the laparoscopic port to wash the incisions and anastomosis.
Study: NCT06182085
Drug: PRI-002
Normalized name: PRI-724
DrugBank: PRI-724 (DB15034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT06655025
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine infusion during open heart surgery
Study: NCT06589089
Drug: autologous hematopoietic stem cell
Normalized name: human cord blood hematopoietic progenitor cell
DrugBank: Human cord blood hematopoietic progenitor cell (DB11054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention were given myelosuppression occurring that cannot be controlled with other drugs as judged by the investigators
Study: NCT06591338
Drug: Ticagrelor 90 MG
Normalized name: ticagrelor 90 MG
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The ticagrelor arm will receive (a 180mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 90mg once daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin
Study: NCT06591338
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The clopidogrel arm will receive (a 300 mg loading dose of clopidogrel during the first 24 hours of stroke onset, followed by 75 mg once daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
Study: NCT05666804
Drug: Brolucizumab 6mg
Normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Brolucizumab 6mg (intravitreal) Personalized regimen arm: 1\~3 x 4-week loading injections and one 8-week injection, followed by Treat-and-extend (T\&E) regimen up to Week 56
Study: NCT05666804
Drug: Brolucizumab 6mg
Normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Brolucizumab 6mg(intravitreal) Standard q12w/q8w regimen arm: 3 x 4-week loading injections and disease activity assessment at week 16 followed by q12w/q8w up to Week 56
Study: NCT04951947
Drug: JS201 combine with Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: JS201 300mg i.v Q2wLenvatinib 8mg po. Qd
Study: NCT00000670
Drug: Probenecid
Normalized name: Probenecid
DrugBank: Probenecid (DB01032)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000670
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04818788
Drug: Biological Drug
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: we will give biological drugs to indicated ulcerative colitis patients and we will investigate the predictive ability of fecal calprotectin and hematological indices to histological remission
Study: NCT05072600
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: pembrolizumab 200 mg Q3W
Study: NCT06169059
Drug: JC-013
Normalized name: CE-VST01-JC
DrugBank: CE-VST01-JC (DB17190)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of JC-013(COX-2 inhibitor))
Study: NCT05007938
Drug: Icotinib
Normalized name: icotinib
DrugBank: Icotinib (DB11737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icotinib is a EGFR ihibitior.
Study: NCT05684211
Drug: Ametumumab
Normalized name: Adecatumumab
DrugBank: Adecatumumab (DB05006)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A recombinant fully human anti-EGFR monoclonal antibody
Study: NCT05684211
Drug: Anti-PD-1 monoclonal antibody
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab 3 mg/kg，Intravenous titration，Q2W
Study: NCT05684211
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab 500 mg/m2 ，Intravenous titration，Q2W
Study: NCT00804921
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00804921
Drug: acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00804921
Drug: brimonidine
Normalized name: Brimonidine
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00279487
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05007938
Drug: Befotertinib
Normalized name: Befotertinib
DrugBank: Befotertinib (DB18844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: An orally available, irreversible, third-generation，mutant-selective epidermal growth factor receptor（EGFR）inhibitor. Befotertinib combine with icotinib means that both drugs will be given together until disease progression or meet the discontinuation criteria.
Study: NCT05245227
Drug: Sublingual Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol 400 mcg sublingual
Study: NCT02531672
Drug: 11C-choline
Normalized name: 11C-choline
DrugBank: Choline C 11 (DB09277)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05245227
Drug: IV Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 units IV Oxytocin in 1000 mL normal saline
Study: NCT00002080
Drug: Rifabutin
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05619172
Drug: Nanrilkefusp alfa
Normalized name: Nanrilkefusp alfa
DrugBank: Nanrilkefusp alfa (DB17480)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) injection
Study: NCT05619172
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous (IV) infusion via peripheral or central venous line
Study: NCT05931601
Drug: Noradrenaline
Normalized name: Noradrenaline
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See arm description
Study: NCT05324852
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam, 5 mg, injectable solution in 5mg/ml, intranasal administration, atomize into nose with Mucosal Atomizer Device (MAD) 5mg(1ml) up each nostril , one time
Study: NCT05324852
Drug: Intramuscular loxapine
DrugBank: Loxapine (DB00408)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loxapine, 100mg, injectable solution in 50mg/2ml intramuscular, intra muscular administration, one time
Study: NCT05038982
Drug: Abrocitinib
Normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: During the study period, subjects will take one Abrocitinib 200 mg tablet once daily orally. Subjects will be directed to take doses of Abrocitinib at approximately the same time of day.
Study: NCT05092217
Drug: Tirelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirelizumab: 200 mg, intravenous injection over 60 minutes (Q3W); Tirelizumab should be applied since 2-6 weeks after surgery until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision, or 1 year.
Study: NCT00002002
Drug: Trimethoprim
Normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002002
Drug: Sulfamethoxazole
Normalized name: Sulfamethoxazole
DrugBank: Sulfamethoxazole (DB01015)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05283109
Drug: Hiltonol
Normalized name: Hiltonol
DrugBank: Hiltonol (DB17293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hiltonol® is made up of synthetic (manmade) RNA (ribonucleic acid) and is used as an adjuvant to the vaccine, meaning it is used with the vaccine to stimulate or enhance the activation of your immune system.
Study: NCT04943627
Drug: Balstilimab (BAL)
Normalized name: Balstilimab
DrugBank: Balstilimab (DB15676)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1 Monoclonal antibody
Study: NCT04943627
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy
Study: NCT04943627
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy
Study: NCT04943627
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy
Study: NCT04943627
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy
Study: NCT04943627
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Chemotherapy
Study: NCT04125472
Drug: Lumasiran
Normalized name: lumasiran
DrugBank: Lumasiran (DB15935)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lumasiran administered as a subcutaneous (SC) injection
Study: NCT05425940
Drug: XL092
Normalized name: XL092
DrugBank: Zanzalintinib (DB17525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplied as tablets; administered orally daily
Study: NCT05425940
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Supplied as 1200 mg/20 mL vials; administered as a 1200 mg IV infusion once in a 3-week cycle (q3w)
Study: NCT05425940
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Supplied as 40 mg tablets; administered orally daily at 160 mg for the first 21 days of each 28-day cycle
Study: NCT05005468
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab is given on the first day of each cycle, intravenous drip.
Study: NCT05005468
Drug: Famitinib
Normalized name: Famitinib
DrugBank: Famitinib (DB11741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famitinib is administered orally, once a day.
Study: NCT05438303
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam will be administered orally as a syrup once on Day 1 of Treatment Periods 1 and 3; administered together with Omeprazole
Study: NCT05438303
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An Omeprazole capsule will be administered once on Day 1 of Treatment Periods 1 and 3; administered together with Midazolam
Study: NCT05438303
Drug: Dabigatran Etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A Dabigatran Etexilate capsule will be administered once on Day 1 of Treatment Periods 1 and 2
Study: NCT06311864
Drug: Daridorexant 50 mg
Normalized name: daridorexant 50 MG
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As indicated by the physician
Study: NCT04753606
Drug: Obicetrapib
Normalized name: Obicetrapib
DrugBank: Obicetrapib (DB14890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets
Study: NCT04548349
Drug: Altreno
Normalized name: Altreno
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acne patients will be assigned to Altreno once daily.
Study: NCT04548349
Drug: Benzoyl peroxide
Normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acne patients will be assigned to BPO leave-on gel once daily.
Study: NCT06329076
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of losartan tablets (50 mg)
Study: NCT04904614
Drug: Letermovir
Normalized name: Letermovir
DrugBank: Letermovir (DB12070)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Open label trial of the licensed drug, letermovir, in a population of heart transplant recipients for which it is not yet licensed
Study: NCT04818372
Drug: CM313-Dose escalation
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single dose of CM313 followed by a 3-week period for DLT observation. After that subjects will have 6 infusions at weekly intervals.
Study: NCT04818372
Drug: CM313
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will have 8 infusions at weekly intervals, and then 8 infusions at bi-weekly intervals. After that CM313 will be given every 4 weeks until disease progression or unacceptable toxicity.
Study: NCT04818372
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexamethasone 40 mg/day at day 1,8,15,22 at 28 days cycle
Study: NCT04818372
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 25 mg/day lenalidomide 21 of 28 days cycle
Study: NCT05825378
Drug: Dexamethasone 8mg+0.375% ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound-guided intercostal nerve block was performed on the surgical side, and 3 to 5ml of a mixture of 0.375% ropivacaine and 8 mg dexamethasone was injected at each point
Study: NCT05825378
Drug: 0.375% ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound-guided intercostal nerve block was performed on the surgical side, and 3 to 5ml 0.375% ropivacaine was injected at each point
Study: NCT06390748
Drug: esmolol
Normalized name: Esmolol
DrugBank: Esmolol (DB00187)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The primary intervention is the administration of Esmolol. Esmolol was specifically used to evaluate its immunomodulatory effects in patients with sepsis in the study. The dosage was tailored to achieve optimal heart rate control, an integral part of the therapeutic strategy aiming to mitigate the hyperadrenergic state often seen in sepsis. Alongside Esmolol, daily electrocardiogram (ECG) monitoring was incorporated to observe any changes in the QT interval, ensuring cardiac safety due to the known potential cardiac effects of beta-blockers.
Study: NCT00002999
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05552937
Drug: Tafasitamab and Lenalidomide
Normalized name: Tafasitamab
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tafasitamab will be administered intravenously in 28-day cycles. During Cycles 1 through 3, tafasitamab will be administered weekly on Days 1, 8, 15, and 22; an additional loading dose will be administered on Cycle 1 Day 4. Starting with Cycle 4, tafasitamab will be administered on Days 1 and 15 of each cycle.~Participants will self-administer lenalidomide capsules orally on Days 1-21 of each 28-day cycle, up to 12 cycles.
Study: NCT05366738
Drug: Vonoprazan
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Orally via tablet
Study: NCT05366738
Drug: Vonoprazan
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Orally via sprinkle pellets
Study: NCT05024032
Drug: Tirzepatide
Normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06405724
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 133mg LB 20mL thoracic paravertebral nerve block
Study: NCT06405724
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5% ropivacaine 20mL thoracic paravertebral nerve block
Study: NCT06119139
Drug: 3.6 ml 4% Articaine hydrochloride
DrugBank: Articaine (DB09009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3.6 ml 4% articaine buccal infiltration
Study: NCT06119139
Drug: 1.8 ml 4% Articaine hydrochloride
DrugBank: Articaine (DB09009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.8 ml 4% articaine buccal infiltration
Study: NCT04941287
Drug: Cobimetinib
Normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT04941287
Drug: Varlilumab
Normalized name: Varlilumab
DrugBank: Varlilumab (DB11930)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05829226
Drug: LYT-200
Normalized name: LYT-200
DrugBank: LYT-200 (DB18179)
Approvals — FDA: no, EMA: no, PMDA: no
Description: monoclonal antibody (mAb), targeting galectin-9 protein
Study: NCT05829226
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bcl-2 inhibitor
Study: NCT05829226
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Hypomethylating agent
Study: NCT05829226
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypomethylating agent
Study: NCT02658396
Drug: GO-203-2C
Normalized name: GO-203-2C
DrugBank: GO-203-2C (DB15008)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02658396
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04801017
Drug: OT-101
Normalized name: OT-730
DrugBank: OT-730 (DB16112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TGF β2 specific synthetic 18 mer phosphorothioate antisense oligodeoxynucleotide
Study: NCT04801017
Drug: Artemisinin
Normalized name: ARTEMISININ
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal Supplement/ Purified extract from Artemisia
Study: NCT05136924
Drug: OC-01 (varenicline 1.2mg/ml) nasal spray vs Placebo
Normalized name: varenicline Nasal Spray
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OC-01 nasal spray containing varenicline for treatment of signs and symptoms of DED. OC-01 (varenicline) nasal spray activates the trigeminal parasympathetic pathway and stimulates natural tear production to bathe the corneal nerve endings in a protective layer of tear film. In addition, OC-01 (varenicline) acts as a cholinergic agonist and may provide analgesia by activating the trigeminal parasympathetic pathway VS Placebo
Study: NCT05036876
Drug: Degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment with insulin degludec when compared to insulin glargine U-300 will result in similar blood glucose control in hospitalized patients with type 2 diabetes.
Study: NCT05036876
Drug: Glargine U300
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment with insulin glargine U300 when compared to insulin degludec will result in similar blood glucose control in hospitalized patients with type 2 diabetes.
Study: NCT04840823
Drug: Enoxacin
Normalized name: Enoxacin
DrugBank: Enoxacin (DB00467)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 200mg tablet
Study: NCT06091826
Drug: NFL-101
Normalized name: NFLX
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous injections
Study: NCT00935675
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram 10 mg once a day
Study: NCT05276804
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The dosing for Sugammadex is 4mg/kg for a deep reversal and a 2mg/kg for a standard reversal, which will be more common for this study. Sugammadex comes in 200mg/2mL and 500mg/5mL vials. Because of the variability in weight of the patients and the type of reversal needed (deep vs standard), 140 5mL vials will be required.
Study: NCT04391049
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenously (IV)
Study: NCT04391049
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenously (IV)
Study: NCT06067217
Drug: Tranexamic acid 250 mg oral tablet
Normalized name: tranexamic acid 250 MG Oral Tablet
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compare between tranexamic acid and progynova to stop abnormal uterine bleeding in DMPA users
Study: NCT05733117
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cholecalciferol
Study: NCT05478837
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT03705338
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recorder the loss and recovery of consciousness in children under general anesthesia with TCI of propofol intravenous. Induction will be started with 20 mg/kg/hr of propofol up to UMSS level 4. Then will be titrated leading anesthesiologist criteria.
Study: NCT05697211
Drug: Ferric maltol 30 mg (Feraccru®)
Normalized name: ferric maltol 30 MG
DrugBank: Ferric maltol (DB15598)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: In this trial Feraccru® 30 mg hard capsules will be used. Each capsule contains 30 mg iron (as ferric maltol), 91.5 mg of lactose, 0.5 mg of Allura Red AC (E129) and 0.3 mg Sunset Yellow FCF (E110) as excipients with known effects.